<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126719</url>
  </required_header>
  <id_info>
    <org_study_id>MRG003-005</org_study_id>
    <nct_id>NCT05126719</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>An Open-Label, Non-randomized, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Miracogen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Miracogen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety, efficacy, pharmacokinetics, and&#xD;
      immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two stages. In Part A, approximately 24 patients will be enrolled to&#xD;
      evaluate the safety and preliminarily efficacy of MRG003. If the prespecified criteria are&#xD;
      met in Part A, this study will enter Part B seamlessly to further evaluate the efficacy and&#xD;
      safety of MRG003. There are two cohorts in Part B, including approximately 79 patients who&#xD;
      have failed the first line standard of care (SOC) in Cohort 1 and approximately 48 patients&#xD;
      who have failed at least two lines of chemotherapy and/or immunotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) by Independent Review Committee (IRC)</measure>
    <time_frame>Baseline to study completion (up to 24 months)</time_frame>
    <description>ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed by Independent Review Committee (IRC) according to RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by Investigator</measure>
    <time_frame>Baseline to study completion (up to 24 months)</time_frame>
    <description>ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed by investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) and Progression Free Survival Rate (PFSR)</measure>
    <time_frame>Baseline to study completion (up to 24 months)</time_frame>
    <description>PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Baseline to study completion (up to 24 months)</time_frame>
    <description>DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Baseline to study completion (up to 24 months)</time_frame>
    <description>DCR is defined as the proportions of patients achieving CR, PR, and stable disease (SD) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to study completion (up to 24 months)</time_frame>
    <description>OS is defined as the duration from the start of treatment to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Baseline to 30 (for AE) and 45 (for SAE) days after the last dose of study treatment.</time_frame>
    <description>Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for MRG003: (Cmax)</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for MRG003: (AUClast)</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment.</time_frame>
    <description>Area under the curve up to the last validated measurable plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for total antibody (TAb): Cmax</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment.</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for TAb: AUClast</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment.</time_frame>
    <description>Area under the curve up to the last validated measurable plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for Monomethyl Auristatin E (MMAE): Cmax</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment.</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for MMAE: AUClast</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment.</time_frame>
    <description>Area under the curve up to the last validated measurable plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with positive ADA immunogenicity results.</measure>
    <time_frame>Baseline to 30 days after the last dose of study treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">151</enrollment>
  <condition>Recurrent or Metastatic Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>MRG003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRG003</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>MRG003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to sign the ICF and follow the requirements specified in the protocol.&#xD;
&#xD;
          -  Age: ≥18 years, both genders.&#xD;
&#xD;
          -  Expected survival time&gt;3 months.&#xD;
&#xD;
          -  Patients with histologically confirmed unresectable, radiation-ineligible recurrent&#xD;
             metastatic nasopharyngeal carcinoma.&#xD;
&#xD;
          -  Part A: Metastatic nasopharyngeal carcinoma that has failed or recurred or was&#xD;
             intolerant to at least two lines of prior systemic therapy with platinum-based&#xD;
             regimens.&#xD;
&#xD;
          -  Part B: Cohort 1: Metastatic nasopharyngeal carcinoma that has failed or recurred or&#xD;
             was intolerant to prior systemic therapy with a first-line platinum-based regimen.&#xD;
             Cohort 2: Metastatic nasopharyngeal carcinoma that has failed or relapsed after or is&#xD;
             intolerant to at least two prior lines of platinum-based systemic therapy.&#xD;
&#xD;
          -  Patients must have measurable lesions according to the Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST v1.1).&#xD;
&#xD;
          -  ECOG performance score 0 or 1.&#xD;
&#xD;
          -  Organ functions and coagulation function must meet the basic requirements.&#xD;
&#xD;
          -  No severe cardiac dysfunction with left ventricular ejection fraction (LVEF) ≥ 50%.&#xD;
&#xD;
          -  Serum or urine pregnancy test negative within 72 hours before the first dose of&#xD;
             investigational drug.&#xD;
&#xD;
          -  Patients with childbearing potential must use effective contraception during the&#xD;
             treatment and for 6 months after the last dose of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Part A: received &lt; 2 prior lines of systemic therapy.&#xD;
&#xD;
          -  Part B: Cohort 1 received two lines of prior therapies; Cohort 2 received the first&#xD;
             line of prior therapy only.&#xD;
&#xD;
          -  History of 4 or more systemic anti-tumor therapies for the recurrent metastatic&#xD;
             nasopharyngeal carcinoma.&#xD;
&#xD;
          -  Expected surgery or any other form of systemic or local anti-tumor therapy.&#xD;
&#xD;
          -  History of systemic chemotherapy, antitumor biological therapy or immunotherapy, or&#xD;
             major surgery within 3 weeks, &gt;30 Gy thoracic radiotherapy within 6 months, prior&#xD;
             radiotherapy within 14 days before the first administration of the investigational&#xD;
             drug.&#xD;
&#xD;
          -  Known active CNS metastasis and/or cancerous meningitis.&#xD;
&#xD;
          -  Residual toxicity reactions caused by previous anti-tumor treatment or abnormal values&#xD;
             of laboratory tests higher than grade 1 (CTCAE v5.0).&#xD;
&#xD;
          -  Uncontrolled or poorly controlled heart disease.&#xD;
&#xD;
          -  History of pulmonary embolism or deep vein thrombosis within 3 months before the first&#xD;
             administration of the investigational drug.&#xD;
&#xD;
          -  Known history of malignancy.&#xD;
&#xD;
          -  Uncontrolled or poorly controlled hypertension.&#xD;
&#xD;
          -  Patients with a history of active bleeding, coagulopathy, or receiving coumarin&#xD;
             anticoagulation therapy.&#xD;
&#xD;
          -  Subjects with a history of ≥ Grade 3 immune-related AEs (irAEs).&#xD;
&#xD;
          -  Known allergic reaction to any ingredients or excipients of MRG003.&#xD;
&#xD;
          -  Known active hepatitis B or C.&#xD;
&#xD;
          -  Complicated with severe, uncontrolled infection or known human immunodeficiency virus&#xD;
             (HIV) infection, or diagnosed as acquired immunodeficiency syndrome (AIDS); or&#xD;
             uncontrolled autoimmune disease; or history of allogeneic tissue/organ&#xD;
             transplantation, stem cell or bone marrow transplantation, or solid organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Active bacterial, viral, fungal, rickettsia, or parasitic infections that require&#xD;
             systemic anti-infective treatment.&#xD;
&#xD;
          -  Vaccination of live virus vaccine within 30 days before the first administration of&#xD;
             the study drug. Inactivated seasonal influenza vaccine or approved COVID-19 vaccine is&#xD;
             allowed.&#xD;
&#xD;
          -  Moderate to severe dyspnea at rest caused by advanced cancer or its complications, or&#xD;
             severe primary lung disease, oxygen saturation &lt; 93% in non-oxygen state, or history&#xD;
             of any interstitial lung disease or interstitial lung disease (ILD) requiring oral or&#xD;
             intravenous glucocorticoids or non-infectious pneumonia.&#xD;
&#xD;
          -  Patients receiving immunology-based treatment for any reason.&#xD;
&#xD;
          -  Chronic autoimmune disease or inflammatory disease requiring systemic therapy or&#xD;
             receiving systemic therapy within the past 2 years.&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion or recurrent ascites.&#xD;
&#xD;
          -  Potent CYP3A4 inhibitors or inducers are in use and cannot be discontinued.&#xD;
&#xD;
          -  Women who are lactating or pregnant.&#xD;
&#xD;
          -  Other conditions that in the clinical judgement of the investigator make the patient&#xD;
             not suitable for participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Program Director</last_name>
    <phone>86-21-61637960</phone>
    <email>clinicaltrials@miracogen.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolei Shu, Doctor</last_name>
      <phone>86-023-65311341</phone>
      <email>1466540113@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sufang Qiu, Doctor</last_name>
      <phone>86-0591-83660611</phone>
      <email>sfqiu@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, Doctor</last_name>
      <phone>86-020-87343392</phone>
      <email>Ruihxu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Jiang, Doctor</last_name>
      <phone>86-0754-88555844</phone>
      <email>jiangzy_123@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yue Bei People's Hospital</name>
      <address>
        <city>Shaoguan</city>
        <state>Guangdong</state>
        <zip>512026</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suming Pan, Doctor</last_name>
      <phone>86-0751-69138369</phone>
      <email>13826331948@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan City People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <zip>528403</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Lei, Doctor</last_name>
      <phone>86- 0760-88823566</phone>
      <email>13528227676@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Song Qu, Doctor</last_name>
      <phone>86- 0771-5331955</phone>
      <email>daisyqs2002@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shenhong Qu, Doctor</last_name>
      <phone>86-0771-2635268</phone>
      <email>2510243342@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanjing Huang, Doctor</last_name>
      <phone>86-0898-963399</phone>
      <email>3307527827@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingrui Shi, Doctor</last_name>
      <phone>86-0731-88651900</phone>
      <email>shiyingrui@hnca.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Gannan Medical University</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingjun Xu, Doctor</last_name>
      <phone>86-21-8689206</phone>
      <email>xumingjun627@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ganzhou Cancer Hospital</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Wu, Doctor</last_name>
      <phone>86-0797-8109362</phone>
      <email>wuweimingzi@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Guo, Doctor</last_name>
      <phone>86-21-38804518</phone>
      <phone_ext>22132</phone_ext>
      <email>pattrickguo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Zhang, Doctor</last_name>
      <phone>86-028-85420305</phone>
      <email>izhangpeng@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yibin Second People's Hospital</name>
      <address>
        <city>Yibin</city>
        <state>Sichuan</state>
        <zip>644000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaijian Lei, Doctor</last_name>
      <phone>86-0831-8886606</phone>
      <email>lkj600@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRG003</keyword>
  <keyword>Antibody Drug Conjugate (ADC)</keyword>
  <keyword>Nasopharyngeal Carcinoma.</keyword>
  <keyword>EGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

